Showing 8771-8780 of 9757 results for "".
- Roflumilast Foam 0.3% Eases Scalp Itch in as Early as 24 hourshttps://practicaldermatology.com/news/roflumilast-foam-03-eases-scalp-itch-in-as-early-as-24-hours/2462068/Arcutis’ roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints when compared to vehicle, according to patient-reported outcome data from the pivotal ARRECTOR Phase 3 trial in scalp and body psoriasis presented at the
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Nevisense Detects Skin Barrier Damage In Skin Sampleshttps://practicaldermatology.com/news/nevisense-detects-skin-barrier-damage-in-skin-samples/2462031/Nevisense can measure skin barrier function in human excised skin samples, SciBase reports. For the study, Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice
- Smart Ring May Objectively Measure Scratching Intensityhttps://practicaldermatology.com/news/smart-ring-may-objectively-measure-scratching-intensity/2462015/A new wearable device may objectively measure the intensity of scratching. Akhil Padmanabha, a PhD student in Carnegie Mellon University's (CMU)
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran
- Spotlight on Snail Mucushttps://practicaldermatology.com/news/spotlight-on-snail-mucus/2461980/Snail mucus is widely used in cosmetics, moisturizers, anti-aging creams, wound care treatments, and antimicrobials, but what is it, really? This was the question posed by researchers in a new study that examines the molecular composition of snail mucus. When analyzing the mucus of a co
- Melanoma Discovery: Understanding the Role of GREB1 Isoform4 in Melanomahttps://practicaldermatology.com/news/melanoma-discovery-understanding-the-role-of-greb1-isoform4-in-melanoma/2461979/GREB1 Isoform4 (Is4) is involved in pyrimidine synthesis and causes malignant melanoma, suggesting GREB1 Is4 a new therapeutic target for melanoma, according to a study in Oncogene. The expression of a specif